WS
BEAM icon

Wedbush Securities’s Beam Therapeutics BEAM Stock Holding History

Wedbush Securities’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-3,925
Closed -$225K – 1078
2022
Q1 		$225K Sell
3,925
-150
-4% -$9.84K 0.01% 933
2021
Q4 		$325K Buy
4,075
+15
+0.4% +$1.28K 0.01% 840
2021
Q3 		$353K Buy
4,060
+35
+0.9% +$3.52K 0.02% 774
2021
Q2 		$518K Buy
4,025
+125
+3% +$9.96K 0.02% 610
2021
Q1 		$312K Buy
3,900
+350
+10% +$33.3K 0.02% 798
2020
Q4 		$290K Buy
+3,550
New +$175K 0.03% 665

Other funds holding BEAM

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Wedbush Securities's BEAM Position: Q2 2022 in Review

Wedbush Securities sold out of Beam Therapeutics (BEAM) in Q2 2022, closing a stake of 3,925 shares — an estimated $225K sold.

Wedbush Securities first reported a position in BEAM in Q4 2020 and held it in 6 quarters. The position peaked at $518K in Q2 2021. 205 funds tracked by Wall St. Rank hold BEAM as of Q2 2022.

  • Wedbush Securities reported no remaining Beam Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Wedbush Securities sold 3,925 Beam Therapeutics shares in Q2 2022, an estimated $225K.
  • Wedbush Securities first reported a position in Beam Therapeutics in Q4 2020 and held it in 6 quarters.
  • Wedbush Securities's Beam Therapeutics position peaked at $518K in Q2 2021.
  • 205 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2022.

Based on Wedbush Securities's 13F filing for Q2 2022, filed 21 Jul 2022.